Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

43.78 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
42 43 Next >
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
Earnings Outlook For GSK
 
Via Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
A Look Into GSK Inc's Price Over Earnings
 
Via Benzinga
Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology
From Elegen
Via Business Wire
GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M
GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake. 
Via Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
What the Options Market Tells Us About GSK
 
Via Benzinga
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer Study
GSK plc (NYSE: GSK)  
Via Benzinga
Looking Into GSK's Recent Short Interest
 
Via Benzinga
Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles
Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning 
Via Benzinga
GSK Boosts Its Asthma Product Portfolio With Over $1B Deal For Aiolos Bio
GSK plc (NYSE: GSK) has agreed to acquire Aiolos Bio Inc 
Via Benzinga
GSK Enters Agreement to Acquire Aiolos Bio
From Aiolos Bio, Inc.
Via Business Wire
GlaxoSmithKline PLC (NYSE: GSK) Records 52-Week High Monday Morning
Via Investor Brand Network
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Why Biopharmaceutical Player CureVac Shares Are Rising Today
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday. 
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Sleeper Hits: 3 Unexpected Stocks Poised for a Breakout in 2024
Many stocks emerge from Wall Street's doghouse relatively quickly. Here are three names that could become surprise breakout stocks for 2024. 
Via InvestorPlace
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year 
Via Talk Markets
Dell To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves
In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion... 
Via Benzinga
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on... 
Via Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
3 Growth at a Reasonable Price (GARP) Stocks for Balanced Growth
GARP stocks are less likely to plunge than growth stocks with high valuations and more likely to generate strong growth than value stocks. 
Via InvestorPlace
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or... 
Via Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
From GSK plc
Via Business Wire
3 cheap 'stock'-ing stuffers Wall Street is bullish on
These three companies have Wall Street feeling bullish and are trading under $10, making them ideal ‘stock'-ing stuffers for hard to shop for traders. 
Via MarketBeat
Topics Stocks
Why Is Genetic Medicines-Focused Wave Life Sciences Stock Trading Lower Today?
Wave Life Sciences Ltd (NASDAQ: WVE) has priced its previously announced underwritten public offering of 20 million shares at $5.00 per share with approximately  
Via Benzinga
These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.